The goal of this cross-sectional single-center study was to investigate the serum concentrations of myokines (irisin, myonectin, and myostatin) in the patients with MASLD and HTN (as a cardiometabolic risk factor, the presence of which is a prerequisite for the diagnosis of MASLD, according to the expert consensus published in 2023 [27]) and to assess their correlation with laboratory parameters that are surrogate markers of metabolic disorders and liver disease activity [40,41,42]. The gene discussed is FNDC5; the disease is metabolic disease.